TON - November 2018, Vol 11, No 5

The CAR product “is essentially an autologous T-cell, which is transduced using a lentiviral encoding vector for a CAR, which is specific to human BCMA,” said Dr Raje. The co-stimulatory domain that includes 4-1BB is believed to be associated with durable CAR T-cell persistence compared with the CD28 co-stimulatory domain.
This clinical trial is the first study to show that this immunotherapy combination is as beneficial in controlling brain metastases as it is in treating extracranial metastases.
A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Key­truda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a preliminary phase 1b clinical trial.
Page 2 of 2
Results 11 - 13 of 13